NEW YORK, July 13, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today
announced it will attend the Alzheimer's Association
International Conference in Denver, July 26-30,
2021. ("AAIC 2021") The AAIC is the largest and
most influential international meeting dedicated to advancing
dementia science. Each year, AAIC convenes the world's leading
basic science and clinical researchers, next-generation
investigators, clinicians, and the care research community to
share research discoveries that will lead to methods of
prevention and treatment and improvements in the diagnosis of
Alzheimer's disease. (https://www.alz.org/aaic/overview.asp).
Anthony Hayes, CEO of AIkido
stated, "We believe that advancing the science of dementia is
important and the treatment of the disease has significant unmet
medical needs. We are excited to be a part of this conference
as we continue to work towards greater diversification of the
Company."
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology Company with a
diverse portfolio of small-molecule anti-cancer therapeutics.
The Company's platform consists of patented technology from leading
universities and researchers, and we are currently in the process
of developing an innovative therapeutic drug platform through
strong partnerships with world renowned educational institutions,
including The University of Texas at Austin and University of
Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the SEC,
not limited to Risk Factors relating to its business contained
therein. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-to-attend-the-alzheimers-association-international-conference-301332594.html
SOURCE AIkido Pharma Inc.